Evidence map›Paper›PMID 40248432›Full record

ArticleFrontiers in microbiology2025

Emergence and characterization of IncFII/IncR plasmids with multiple 5,692 bp-

Hongmao Liu, Mei Zhu, Junwan Lu, Shan Wu, Rujian Ye, Wei Pan, Yirong Li, Qiyu Bao, Dawei Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hongmao Liu *Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Mei Zhu *Department of Clinical Laboratory, Zhejiang Hospital, Hangzhou, China.
Junwan LuSchool of Laboratory Medicine and Life Sciences, Institue of Biomedical Informatics, Wenzhou Medical University, Wenzhou, China.
Shan WuDepartment of Clinical Laboratory, The People's Hospital of Yuhuan, Taizhou, China.
Rujian YeDepartment of Clinical Laboratory, The People's Hospital of Yuhuan, Taizhou, China.
Wei PanDepartment of Clinical Laboratory, The People's Hospital of Yuhuan, Taizhou, China.
Yirong LiDepartment of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Qiyu BaoSchool of Laboratory Medicine and Life Sciences, Institue of Biomedical Informatics, Wenzhou Medical University, Wenzhou, China.
Dawei HuangDepartment of Clinical Laboratory, The People's Hospital of Yuhuan, Taizhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ceftazidime/avibactam (CAZ/AVI) is widely recognized as an effective treatment for infections caused by KPC-producing

Indexed as

5,692 bp-tandem repeatblaKPC-2Ceftazidime/avibactamhypervirulentKlebsiella pneumoniae

Identifiers

PMID40248432
PMCPMC12003348

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.